This site includes summaries of completed clinical trials, and will be expanded as ongoing trials are completed.

The information contained here is intended for healthcare professionals. For patients visiting this web site, the contents are not intended to replace the informed medical advice or medical treatments recommended by a health care professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional.

The studies listed here may include approved and non-approved uses, formulations or treatment regimens. The results of any single study may not reflect the overall results obtained on all studies of a product. Before prescribing any product mentioned here, healthcare professionals should consult the prescribing information for the product, if approved in their country, or the Investigator's Brochure for non-marketed drugs.

Please note that in some instances, there may be a delay in posting some data in the trial summaries as they be regarded as sensitive for competitive reasons, patent approval, or to comply with policies of medical journals to which manuscripts have been submitted for publication. Additionally, Purdue Pharma may be required to withhold certain trial summaries to comply with confidentiality provisions in agreements with other parties.

The IFPMA protocol requires that results of trials be posted within one year after the drug is first approved and commercially available or within one year of trial completion, unless such postings compromise publication in peer-reviewed medical journals or contravene national laws or regulations. Furthermore, the proposal applies to clinical trials completed since the publication date of the IFPMA joint position statement of January 6, 2005.

Long-term open label extension of a double-blind, randomized, placebo-controlled trial of controlled release (cr) tramadol (Zytram XL®) in patients with chronic osteoarthritis pain. Abstract.

A randomized, double-blind, crossover comparison of buprenorphine transdermal system (BTDS) and placebo in patients with chronic low back pain. Abstract.

Randomized placebo controlled trial of buprenorphine transdermal system in patients with chronic low back pain. Abstract.

An Evaluation of Patient and Physician Satisfaction with Controlled-Release Oxybutynin 15mg as a One-Step Daily Dose in Elderly and Non-Elderly Patients with Overactive Bladder: Results of the STOP Study. Abstract.

To Ongoing Clinical Trials